Is Pieris Pharmaceuticals Stock a Good Investment?
Pieris Pharmaceuticals Investment Advice | PIRS |
- Examine Pieris Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pieris Pharmaceuticals' leadership team and their track record. Good management can help Pieris Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pieris Pharmaceuticals' business and its evolving consumer preferences.
- Compare Pieris Pharmaceuticals' performance and market position to its competitors. Analyze how Pieris Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Pieris Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pieris Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pieris Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pieris Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Pieris Pharmaceuticals Stock
Researching Pieris Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 53.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pieris Pharmaceuticals recorded a loss per share of 12.11. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 23rd of April 2024.
To determine if Pieris Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pieris Pharmaceuticals' research are outlined below:
| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Pieris Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Marketscreener.com |
Pieris Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Pieris Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pieris Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pieris Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pieris Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pieris Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-09 | 2018-06-30 | -0.01 | -0.0038 | 0.0062 | 62 | ||
2022-11-02 | 2022-09-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2022-08-04 | 2022-06-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2023-05-10 | 2023-03-31 | -0.14 | -0.18 | -0.04 | 28 | ||
2022-05-11 | 2022-03-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2019-08-09 | 2019-06-30 | -0.2 | -0.24 | -0.04 | 20 | ||
2017-11-08 | 2017-09-30 | -0.21 | -0.16 | 0.05 | 23 | ||
2016-03-22 | 2015-12-31 | -0.12 | -0.07 | 0.05 | 41 |
Know Pieris Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pieris Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pieris Pharmaceuticals backward and forwards among themselves. Pieris Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Pieris Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 164 | U.s. Bancorp | 2024-06-30 | 158 | Barclays Plc | 2024-06-30 | 63.0 | Wells Fargo & Co | 2024-06-30 | 60.0 | Jpmorgan Chase & Co | 2024-06-30 | 27.0 | Bank Of America Corp | 2024-06-30 | 13.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 7.0 | Hanson Mcclain Inc | 2024-09-30 | 5.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Bvf Inc | 2024-09-30 | 257.6 K | Bml Capital Management Llc | 2024-09-30 | 42.1 K |
Pieris Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.14 M.Market Cap |
|
Pieris Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.67) | |
| Return On Capital Employed | (1.11) | (1.17) | |
| Return On Assets | (0.63) | (0.67) | |
| Return On Equity | (0.92) | (0.96) |
Determining Pieris Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Pieris Pharmaceuticals is a good buy. For example, gross profit margin measures Pieris Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pieris Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pieris Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pieris Pharmaceuticals. Check Pieris Pharmaceuticals' Beneish M Score to see the likelihood of Pieris Pharmaceuticals' management manipulating its earnings.
Evaluate Pieris Pharmaceuticals' management efficiency
Pieris Pharmaceuticals has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8046) %, meaning that it created substantial loss on money invested by shareholders. Pieris Pharmaceuticals' management efficiency ratios could be used to measure how well Pieris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2024. Return On Capital Employed is likely to drop to -1.17 in 2024. At this time, Pieris Pharmaceuticals' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 12.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 23.77 | 33.75 | |
| Tangible Book Value Per Share | 23.77 | 33.75 | |
| Enterprise Value Over EBITDA | 0.04 | 0.04 | |
| Price Book Value Ratio | 0.61 | 0.58 | |
| Enterprise Value Multiple | 0.04 | 0.04 | |
| Price Fair Value | 0.61 | 0.58 | |
| Enterprise Value | 126.1 M | 67.6 M |
The strategic initiatives led by Pieris Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.662 |
Basic technical analysis of Pieris Stock
As of the 22nd of November, Pieris Pharmaceuticals holds the Risk Adjusted Performance of (0.01), coefficient of variation of (5,043), and Variance of 5.67. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pieris Pharmaceuticals, as well as the relationship between them. Please check Pieris Pharmaceuticals coefficient of variation and value at risk to decide if Pieris Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 15.93 per share. Given that Pieris Pharmaceuticals has information ratio of (0.06), we recommend you to check out Pieris Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.Pieris Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pieris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pieris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pieris Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pieris Pharmaceuticals' Outstanding Corporate Bonds
Pieris Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pieris Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pieris bonds can be classified according to their maturity, which is the date when Pieris Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Pieris Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pieris Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 1.68 | |||
| Coefficient Of Variation | (5,043) | |||
| Standard Deviation | 2.38 | |||
| Variance | 5.67 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (3.40) | |||
| Potential Upside | 3.23 | |||
| Skewness | 0.9315 | |||
| Kurtosis | 2.55 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 1.68 | |||
| Coefficient Of Variation | (5,043) | |||
| Standard Deviation | 2.38 | |||
| Variance | 5.67 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (3.40) | |||
| Potential Upside | 3.23 | |||
| Skewness | 0.9315 | |||
| Kurtosis | 2.55 |
Consider Pieris Pharmaceuticals' intraday indicators
Pieris Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pieris Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pieris Pharmaceuticals Corporate Filings
F3 | 18th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 8th of November 2024 Other Reports | ViewVerify |
Pieris Stock media impact
Far too much social signal, news, headlines, and media speculation about Pieris Pharmaceuticals that are available to investors today. That information is available publicly through Pieris media outlets and privately through word of mouth or via Pieris internal channels. However, regardless of the origin, that massive amount of Pieris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pieris Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pieris Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pieris Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pieris Pharmaceuticals alpha.
Pieris Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pieris Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pieris Pharmaceuticals Corporate Management
| Florian Witte | VP Leadership | Profile | |
| Maria Kelman | Executive Relations | Profile | |
| Prompong Chaikul | Chief Officer | Profile | |
| Ahmed JD | Chief VP | Profile | |
| Gordon MD | Head Oncology | Profile |
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.